Enliven Therapeutics Inc · Q1 2020 earnings

Briefing

Imara Inc. reported financial results for the first quarter ended March 31, 2020 and reviewed recent business highlights.

Imara Inc. reported a net loss attributable to common stockholders of $15.1 million, or $4.31 per share, for the first quarter of 2020. The company's cash, cash equivalents and investments were $105.9 million as of March 31, 2020, and expects this, along with additional proceeds, will fund operations into mid-2022.

• Closed initial public offering (IPO) in March 2020 with gross proceeds of $75.2 million.
• Progressed clinical trials towards initiating Phase 2b studies in sickle cell disease and beta-thalassemia.
• Strengthened Board of Directors with the addition of Edward E. Conner, M.D., in April 2020 and expanded leadership team with the appointment of Stephen M. Migausky as Senior Vice President, Legal and General Counsel on May 4, 2020.
• Launched ‘Real Impact’ community support grants and program to support nonprofit, community-based organizations serving families impacted by sickle cell disease and beta-thalassemia.

Headline financials

Revenue & EPS history

Imara Inc. provided financial guidance for the full-year 2020, expecting research and development expenses to range between $35 million and $40 million, and general and administrative expenses to range between $8 million and $10 million.